Who is sponsoring NCT05446610?

NCT05446610 is sponsored by Örebro University, Sweden.

What drugs are being tested in NCT05446610?

Interventions in NCT05446610: Fermented product of Pleurotus eryngii mushroom.

Is NCT05446610 still recruiting?

NCT05446610 is currently completed. Last updated 6 July 2022.

Last reviewed 2022-07-06 · How we verify

NCT05446610: FUNglucan

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Investigating Effects in Intestinal Permeability of Rich in Beta-glucans Pleurotus Eryngii Mushrooms Fermentation Supernatants: an Ex-vivo Study

Completed NA Last updated 6 July 2022

What this trial tests

NA trial testing Fermented product of Pleurotus eryngii mushroom in Healthy in 10 participants. Completed in 17 June 2022.

Timeline

17 March 2020

Primary endpoint
18 September 2020

17 June 2022

Quick facts

Lead sponsor	Örebro University, Sweden
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	basic science
Enrollment	10
Start date	17 March 2020
Primary completion	18 September 2020
Estimated completion	17 June 2022
Sites	1 location across Sweden

Drugs / interventions tested

Fermented product of Pleurotus eryngii mushroom

Conditions studied

Healthy — all drugs for Healthy →

Sponsor

Örebro University, Sweden

Who can join

Adults 18 to 65, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the present study was to investigate the ability of Pleurotus eryngii mushrooms fermentation products (FS) to counteract induced intestinal hyperpermeability in human colonic tissues in an ex vivo system.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

<i>Pleurotus eryngii</i> Mushrooms Fermented with Human Fecal Microbiota Protect Intestinal Barrier Integrity: Immune Modulation and Signalling Pathways Counter Deoxycholic Acid-Induced Disruption in Healthy Colonic Tissue.
Kerezoudi EN, Zervakis GI, Pletsa V, Kyriacou A, et al · · 2025 · cited 2× · PMID 40005021 · DOI 10.3390/nu17040694

Verify or expand the search:

Other recruiting trials for Healthy

Currently open trials in the same condition.

NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting

Other Örebro University, Sweden trials

Trials by the same sponsor.

NCT07521709 — Evaluation of an Online ACT and Compassion-based Intervention for Disorders of Gut-Brain Interaction · NA · not yet recruiting
NCT07350239 — Clinical, Microbial and Tissue-based Characterization of Patients Treated for Severe Temporomandibular Joint Pathology · not yet recruiting
NCT07527793 — Monitoring Changes in Blood Circulating Metabolites Using Minimally Invasive Techniques · NA · recruiting
NCT07175402 — Feasibility and Acceptability of an Online ACT Intervention for Disorders of Gut-Brain Interaction - Beta Trial · NA · completed
NCT06887751 — Feasibility and Acceptability of an Online ACT Intervention for Disorders of Gut-Brain Interaction · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05446610 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Örebro University, Sweden
Last refreshed: 6 July 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05446610.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing